Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immuneering Corp Cl A (NQ: IMRX )

1.220 -0.110 (-8.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,227,547
Open 1.120
Bid (Size) 1.180 (1)
Ask (Size) 1.210 (2)
Prev. Close 1.330
Today's Range 1.100 - 1.350
52wk Range 1.050 - 10.49
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why is Immuneering (IMRX) Stock Up 24% Today?
Up nearly 25% in today's session on a fast track designation for a key pancreatic cancer drug candidate, IMRX stock is coming into focus. 
Via InvestorPlace
Nasdaq Surges 1%; Meta Posts Upbeat Earnings
Via Benzinga

Performance

YTD
-83.33%
-83.33%
1 Month
+11.93%
+11.93%
3 Month
-26.06%
-26.06%
6 Month
-77.90%
-77.90%
1 Year
-87.58%
-87.58%

More News

Read More
Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Immuneering to Present at the Jefferies Global Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024
Via InvestorPlace
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Immuneering Recognizes Melanoma Awareness Month
From Immuneering Corporation
Via GlobeNewswire
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
From Immuneering Corporation
Via GlobeNewswire
3 Stocks Insiders Are Buying That Analysts Love
Via MarketBeat
March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI
Via AB Newswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial Data
Via Benzinga
Dow Falls Over 200 Points; Adobe Shares Plunge
Via Benzinga
Topics Stocks
Exposures US Equities
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Crude Oil Edges Lower; US Consumer Sentiment Falls In March
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
What's Going On With Cancer-Focused Immuneering Stock On Thursday?
Via Benzinga
US Stocks Higher; Producer Prices Rise 0.6% In February
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.